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Abstract

Liquid biopsies represent an array of plasma analysis tests that are studied to
evaluate and identify circulating tumor products, especially circulating tumor cells
(CTCs) and circulating tumor DNA (ctDNA). Examining such biomarkers in the
plasma of colorectal cancer patients has attracted attention due to its clinical
significance in the treatment of malignant diseases. Given that tissue samples are
sometimes challenging to procure or unsatisfactory for genomic profiling from
patients with colorectal cancer, trustworthy biomarkers are mandatory for guiding
treatment, monitoring therapeutic response, and detecting recurrence.
This review considers the relevance of flowing tumor products like circulating
tumor cells (CTCs), circulating tumor DNA (ctDNA), circulating messenger RNA
(mRNA), circulating micro RNA (miRNA), circulating exosomes, and tumor
educated platelets (TEPs) for patients with colorectal cancer.
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Highlights

✓ Circulating tumor cells and circulating tumor DNA serve as a promising step forward
in the detection and monitoring of colorectal cancer.
✓ More extensive research is required to determine the extent to which liquid biopsies
would be able to impact the patient diagnosis and therapy
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Introduction
Colorectal cancer represents one of the dominant
causes of mortality globally, and through precision
medicine it has become one of the most promising areas
for cancer therapy (1). Colorectal cancer appears in the
colon or rectum, part of the large intestine. The
preponderance
of
colorectal
cancers
are
adenocarcinomas. Most of these cancers develop as a
result of aging and lifestyle, with only a negligible
proportion determined by genetic factors (2). Included
among the risk factors are sedentary lifestyle, smoking,
and obesity. Dietary factors, inflammatory bowel
disease, and several genetic disorders also play a
significant part in the evolution of colorectal cancer (3).
Bowel cancer can be diagnosed by medical imaging and
biopsy, but these procedures usually detect tumors only
in the latter stages of development (2, 3).
In recent years, increasing attention has been given
to liquid biopsy, centering mainly on the examination
and determination of circulating tumor cells (CTC) and
circulating cell-free tumor DNA (ctDNA) because of its
relevance to precision medicine. The study of circulating
tumor products has opened a new, important and precise
pathway to diagnostic medicine. Traditional serum
biomarkers are becoming inadequate for therapeutic
guidance; because of its non-invasive nature and the
amount of information obtained about the tumor, liquid
biopsy has been increasingly considered for colorectal
cancer diagnosis and therapeutic and recurrence
monitoring (4).
For patients with colorectal malignancies, it is
always beneficial to diagnose and genotype tumors using
blood-based biopsies, but sometimes tumor tissue
samples may be insufficient or difficult to procure due to
the low quantity of tumor content and given the invasive
nature for collecting samples. Liquid biopsies offer
substantial information about inter- and intra-tumoral
heterogeneity, in addition to revealing dominant
mutation and relevant subclones of the tumor burden (5,
6).
This review evaluates the potential of this
circulating tumor product to help identify new cancers,
reveal recurrences, classify sensitivity, determine
resistance, and predict prognosis.

leukocytes in the blood of cancer patients, so detection
technologies are adopted in conjunction with enrichment
procedures. The exclusive medical device cleared by the
Food and Drug Administration (FDA) for CTC
enumeration and selection is the CellSearch System
(Veridex, New Jersey, USA).
To use this detection method effectively, CTCs must
have the following properties: the staining pattern must
be cytokeratin phycoerythrin and the fluorescent stain
DAPI (4',6-diamidino-2-phenylindole) needs to be
positive; also the leukocyte common antigen CD45 has
to be negative, the shape of the cell has to be round with
a minimum size of 4um, and lastly, the nucleus ought to
be visible (8).
This system also detects a specific protein called
antibodies against epithelial cell-adhesion molecule
(EpCAM). The EpCAM protein is found exclusively on
the exterior surface of the circulating tumor cells.
CellSearch System pulls the CTCs out, using a magnetic
field, after the EpCam antibodies are previously attached
to a magnetic bead (9). But even after taking such effects
into consideration, CTCs are rarely used in CRC because
of their low numbers (approximately 2 cells per 7,5ml of
blood) (10) (Figure 1).

Figure 1. The CellSearch technology

• ctDNA

In patients with CRC, ctDNA can be detected in 48–
73% of patients (11), and in the case of advanced
metastatic gastrointestinal cancers, the detection rate
increases to almost 100%, so for this reason ctDNA is
more useful than CTCs. In order to detect ctDNA, a gene
mutation has to exist in the tumor genome, with the
genes most probably mutated being APC, TP53, and
KRAS. In recent years many sensitive methods for
detecting ctDNA have been developed, such as:
BEAMing (12), Safe-SeqS, TamSeq (13), and digital
PCR (14, 15).
The BEAMing technique (beads, emulsify-cation,
Discussion
amplification and magnetics) is very precise, detecting
➢ Accepted detection methods of circulating PIK3CA mutation from the ctDNA in the peripheral
blood (16). Over the past several years there has been an
tumor products
increesed need for oncological medication that focuses
• CTCs
directly on mutated genes (17, 18). The first stage of the
CTC presence was first confirmed 140 years ago (7). BEAMing technique purifies the ctDNA. In the second
CTCs are rare, often as low as one cell in 10.000.000 stage, the ctDNA is amplified with the help of the PCR
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technique. In the third step, specific ctDNA sequences
undergo an emulsion process, so that in the fourth and
final stages the sequences attach themselves to magnetic
microbeads and thus can be easily isolated (19, 20).
In conclusion, the BEAMing technique is important
because of its ability to isolate and quantify different
gene mutations, even when in very low quantity.

• mRNAs and miRNA
Circulating messenger RNA and circulating micro
RNA were first detected and analyzed in the late 1990s
using the quantitative reverse transcriptase (qRT)PCR method. Later, mRNAs were identified in the
peripheral blood of colorectal cancer patients (21, 22).
Some methods determine hTERT mRNA as a marker for
colorectal cancer through telomerase activity since it is
generally suppressed in healthy tissues. miRNAs are
stable in blood and plasma and can be measured using
the qRT-PCR method, followed by the TaqMan PCR
method. The TaqMan technique, initially developed in
1991 by Cetus Corporation, is constructed in such a way
that, using a fluorogenic probe, it can isolate a specific
RNA gene sequence. TaqMan method is especially used
to maximize the precision of the PCR technique (23, 24).

• Exosomes

diagnosed with cancer and 55 were healthy individuals.
The study correctly diagnosed the cancer patients using
TEPs in 96% of cases, demonstrating that TEPs modify
mainly according to the type of cancer and in a very low
percentage by the gravity of the disease or metastases. In
summary, the power of TEPs to positively show the
location of the tumor could potentially advance the usage
of liquid biopsies in diagnostic oncology (28, 29).
➢ Biomarkers role in the screening of patients with
CRC
Current screening methods include imaging, blood
protein tests, histologic diagnostic, and direct
visualization, but many of these tests cause discomfort
(colonoscopies) or are unpleasant (stool studies) for the
patient, and they may expose the patient to radiation (CT
scans). Liquid biopsy is a non-invasive procedure having
minimal risk for the patient. Furthermore, liquid biopsy
offers the potential for studying the genomic evolution of
the disease. In 2014, the US Food and Drug
Administration approved the Cologuard test which
detects abnormal fecal DNA and fecal hemoglobin (30).
This test assesses DNA alterations which are distinct for
the primary tumor, including abnormal methylated Bone
morphogenetic protein 3, also known as osteogenin, the
NDRG4 gene that is an alteration of the KRAS gene, the
human beta-actin gene, and hemoglobin metalloprotein.
In 2016, the FDA approved Epi proColon (Epigenomics,
Berlin, Germany), a test that detects and examines the
differential blood biomarker, methylated Septin 9 DNA.
This marker is methylated in colorectal cancer. This test
is possible with the use of the Real-Time PCR method.
In 2014, Perrone et al. (31) directed a study in a high-risk
population for colorectal cancer assessing circulating
tumor DNA adopting the PCR method. The research
revealed that ctDNA was prognosticative for colorectal
cancer; however, it was not predictive for premalignant
lesions, indicating that ctDNA represents an important
complementary screening method in addition to
traditional explorations (32, 33).

Recently it had been discovered that circulating
exosomes could be identified in the plasma of cancer
patients. These exosomes transport genetic material that
can be utilized to monitor the tumor. This type of micro
and nano circulating tumor product is extremely
important in the detection and monitoring of the early
stages of cancer. Conventional techniques for isolation
are ultracentrifugation and density gradient separation,
but these methods are impractical and time consuming
(25). In recent years, a number of scientific techniques
have been perfected that can detect and isolate exosomes.
Plasmonic exosome detection, also known as SPR
(Surface Plasmon Resonance), is a highly sensitive
method able to detect as low as 1 molecule.
Weissleder/Lee group established a sensor named ➢ Pronostic value
nPLEX (nano plasmonic exosome) that has multiple
In colorectal cancer there is demand for
nanohole arrays that are able to detect all types of
supplementary prognostic markers to improve the
exosomes (26, 27).
managment of affected patients. Because circulating
• TEPs (Tumor Educated Platelets)
tumor products like CTCs and ctDNA are directly
Tumor educated platelets (TEPs) are the result of the associated with the tumor burden, they can represent
synergy between tumor cells and blood platelets. TEPs valuable independent prognostic biomarkers (Figure 2).
play an important role in tumor proliferation by Both CTCs and ctDNA are shown to correspond with
modifying the RNA genetic profile. Of all liquid survival in the case of colorectal cancer patients. A
biopsies, TEPs are probably the most important in recent study supervised by Spindler et al. that included
detection. Best et al. (2015) initially discovered their 229 patients with chemotherapy refractory mCRC and
value in diagnostic oncology. Their research used the 100 healthy individuals showed that patients with low
peripheral blood of 283 patients, of whom 228 were later concentrations of ctDNA had a signifficantly higher rate
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of survival than those with higher levels of ctDNA (19).
However, in a study directed by Cohen et al. in 2009,
430 patients with metastatic colorectal cancer were
divided into 2 separate groups based on the levels of
CTCs, those that had <3CTCs per 7,5ml of plasma, and
those that had >3CTCs per 7,5ml of plasma. Their results
showed that patients having lower quantities of CTCs
have almost twice the survival rate of those with higher
quantities of CTCs (34). The amount of CTCs in the
plasma of patients diagnosed with colorectal cancer is
lower than in other types of cancer. A study by Deneve
et al. on 75 patients diagnosed with CRC in situ and
metastatic colorectal cancer, that studied the count of
CTCs in both peripheral and mesenteric blood, showed a
significant discrepancy between the two, therefore
supporting the idea that the liver acts as a filter for CTCs
in colorectal cancer (35).

Figure 2. Clinical value of circulating tumor cells
and circulating tumor DNA for cancer patients.
➢

Detection of resistance to therapies
The objective of personalized cancer therapy is to

uncover a cancer’s particular genes and proteins that
permit the cancer cells to multiply, expand, and
withstand aggressive therapy (36). KRAS and NRAS
gene alterations are currently accepted as biomarkers that
foretell resistance to anti-epidermal growth factor
receptor (anti-EGFR) (37) (Figure 3). In a recent study
organized by Spindler et al. (38) that included 105
patients previously diagnosed with methastatic colorectal
cancer (mCRC) indicated that KRAS mutations occured
in 38% of patients that initially reacted to anti-EGFR

of attained resistance in the evolution of KRAS
mutations (39, 40).

Figure 3. EGFR signaling in both Wild Type KRAS
and Mutated KRAS.

Conclusions
Given that cancers are associated with mutated
genes, it is only normal that genetic analysis should be
included in recent years for the diagnosis, prognosis, and
treatment of patients. Tumors discharge CTCs in the
peripheral blood and these cells release circulating tumor
DNA; thus, researchers have developed a number of
detection technologies for the analysis of such mutations.
More extensive research is required to determine the
extent to which liquid biopsies impact patient care, but
we can now conclude that circulating tumor cells (CTC)
and circulating tumor DNA (ctDNA) serve as a
promising step forward in the detection and monitoring
of colorectal cancer.
The power of liquid biopsies from the peripheral
blood to diagnose and monitor cancers could eventually
simplify the management of oncological diseases, lower
costs by focusing treatment, and eliminate unpleasant
diagnostic tests for patients.
Liquid biopsy has the capacity to manage the
complete array of colorectal cancer diseases. The study
of circulating tumor material in the plasma has
demonstrated the ability to diagnose the disease from
early stages of development and, more importantly, to
enable oncology caretakers the possibility of highly
targeted drug therapy. Studying circulating tumor
products gives researchers a chance to better understand
the process of recurrence and metastasation in colorectal
cancer.
In conclusion, the understanding of circulating
tumor products is likely to transform the way clinicians
approach colorectal cancer disease in the near future.
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